Maucher, A. and Angerer, E. von
(1993)
Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
Journal of cancer research and clinical oncology 119 (11), pp. 669-674.
Full text not available from this repository.
at PubMed
at publisher (via DOI)
Abstract
The nonsteroidal antiandrogen casodex has been described as a peripherally selective drug for the treatment of prostatic cancer. In this study we determined its activity in various models of hormone-dependent malignancies including those of the prostate and the breast. Analysis of endocrine effects in rats after 15 days of treatment revealed a strong reduction of the weights of prostates and ...
Abstract
The nonsteroidal antiandrogen casodex has been described as a peripherally selective drug for the treatment of prostatic cancer. In this study we determined its activity in various models of hormone-dependent malignancies including those of the prostate and the breast. Analysis of endocrine effects in rats after 15 days of treatment revealed a strong reduction of the weights of prostates and seminal vesicles and a significant rise of testosterone serum levels as a result of the interference with central feedback mechanisms. The growth of androgen-sensitive human LNCaP/FGC prostate cancer cells was strongly inhibited by casodex. Unlike hydroxyflutamide, casodex was also active in hormone-depleted medium. The inhibitory effect was overcome by addition of testosterone propionate, which indicates an androgen-receptor-mediated mode of action. In rats bearing Dunning R3327-G prostate carcinomas casodex exerted a strong antitumour effect at the beginning of therapy. However, after 4 weeks of treatment tumours resumed growth whereas diethylstilboestrol-treated tumours remained static. In MXT-M3.2 mouse mammary tumours with significant quantities of androgen receptors casodex was also effective in inhibiting tumour growth. After 6 weeks of treatment, tumour weights were reduced by 69% whereas uterine weights were significantly increased, possibly because of a progestin-like activity of the drug. Csodex is very active in various models of hormone-dependent carcinomas. However, the limited duration of action in prostatic tumours and the incomplete growth inhibition in mammary tumours suggest that it should be used only combination with other endocrine therapies.
Export bibliographical data
| Item type: | Article |
|---|
| Date: | 1993 |
|---|
| Institutions: | Chemistry and Pharmacy > Institute of Pharmacy > Pharmaceutical/Medicinal Chemistry II (Prof. Buschauer) |
|---|
| Identification Number: | | Value | Type |
|---|
| 8349724 | PubMed ID | | 10.1007/BF01215986 | DOI |
|
|---|
| Classification: | | Notation | Type |
|---|
| Androgen Antagonists/pharmacology | MESH | | Anilides/pharmacology | MESH | | Animals | MESH | | Antineoplastic Agents/pharmacology | MESH | | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | MESH | | Cell Division/drug effects | MESH | | Diethylstilbestrol/therapeutic use | MESH | | Female | MESH | | Flutamide/pharmacology | MESH | | Male | MESH | | Mammary Neoplasms, Experimental/drug therapy | MESH | | Mice | MESH | | Neoplasms, Hormone-Dependent/drug therapy | MESH | | Nitriles | MESH | | Prostatic Neoplasms/drug therapy | MESH | | Rats | MESH | | Rats, Inbred F344 | MESH | | Receptors, Androgen/metabolism | MESH | | Testosterone/antagonists & inhibitors | MESH | | Tosyl Compounds | MESH | | Tumor Cells, Cultured/drug effects | MESH |
|
|---|
| Keywords: | Nonsteroidal antiandrogen; LNCaP prostate carcinoma cells; Dunning R3327-G tumour; MXT mouse mammary tumour |
|---|
| Dewey Decimal Classification: | 500 Science > 570 Life sciences
500 Science > 540 Chemistry & allied sciences |
|---|
| Status: | Published |
|---|
| Refereed: | Yes, this version has been refereed |
|---|
| Created at the University of Regensburg: | Yes |
|---|
| Item ID: | 4758 |
|---|
Altmetric